Corebridge Financial Inc. Lowers Stake in Progyny, Inc. (NASDAQ:PGNY)

Corebridge Financial Inc. decreased its position in Progyny, Inc. (NASDAQ:PGNY) by 12.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 42,047 shares of the company’s stock after selling 6,192 shares during the quarter. Corebridge Financial Inc.’s holdings in Progyny were worth $725,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in shares of Progyny by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 8,692,132 shares of the company’s stock valued at $149,939,000 after buying an additional 48,271 shares during the period. Pacer Advisors Inc. increased its stake in Progyny by 47.5% during the fourth quarter. Pacer Advisors Inc. now owns 3,676,200 shares of the company’s stock worth $63,414,000 after purchasing an additional 1,183,558 shares during the period. State Street Corp lifted its position in shares of Progyny by 4.5% during the third quarter. State Street Corp now owns 3,113,654 shares of the company’s stock worth $52,185,000 after purchasing an additional 134,861 shares in the last quarter. River Road Asset Management LLC purchased a new position in shares of Progyny in the fourth quarter valued at approximately $25,529,000. Finally, Fort Washington Investment Advisors Inc. OH grew its holdings in shares of Progyny by 90.1% in the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 1,467,780 shares of the company’s stock valued at $25,319,000 after purchasing an additional 695,740 shares in the last quarter. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PGNY has been the subject of several recent research reports. JPMorgan Chase & Co. raised their price target on shares of Progyny from $17.00 to $23.00 and gave the company a “neutral” rating in a research report on Tuesday, January 28th. Canaccord Genuity Group lifted their target price on Progyny from $17.00 to $23.00 and gave the company a “hold” rating in a report on Friday, February 28th. BTIG Research raised Progyny from a “neutral” rating to a “buy” rating and set a $28.00 target price for the company in a research note on Monday, March 31st. Finally, Bank of America increased their price target on Progyny from $21.00 to $25.00 and gave the company a “buy” rating in a research report on Tuesday, February 11th. Eight research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, Progyny presently has an average rating of “Hold” and an average target price of $23.64.

Progyny Stock Down 2.4 %

PGNY stock opened at $22.60 on Monday. The business has a 50 day moving average price of $22.19 and a 200 day moving average price of $18.45. The stock has a market cap of $1.93 billion, a price-to-earnings ratio of 38.97, a PEG ratio of 2.39 and a beta of 1.33. Progyny, Inc. has a fifty-two week low of $13.39 and a fifty-two week high of $36.36.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.